Discover and read the best of Twitter Threads about #LancetCardiology
Most recents (3)
Presenting now #ESCCongress—#CVD remains leading cause of mortality globally, accounting for 40% of deaths, but in HIC, #cancer is now responsible for twice as many deaths: findings from #PUREStudy
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kyVcg0
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kyVcg0
Presenting now #ESCCongress—Modifiable risk factors account for 70% of all #CVD cases globally, with wide variation is risk factors between countries: findings from #PUREStudy
Free to read with reg until Sept 10 #LancetCardiology
hubs.ly/H0kyVyD0
Free to read with reg until Sept 10 #LancetCardiology
hubs.ly/H0kyVyD0
Cancer's global epidemiological transition and growth: Comment by Jonathan Kocarnik on #PUREStudy published today for #ESCCongress
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kzcn60
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kzcn60
At #ESCCongress? Visit @ElsevierConnect booth number B560 to pick up a free copy of our #LancetCardiology issue hubs.ly/H0kycNh0 including a new series on ischaemic heart disease hubs.ly/H0kychm0 Not attending? Free to read with reg until Sept 10
@ElsevierConnect Primary prevention of ischaemic heart disease: populations,
individuals, and health professionals by R Gupta et al
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kykmJ0
individuals, and health professionals by R Gupta et al
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kykmJ0
@ElsevierConnect Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options by K Ray et al
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kz3HB0
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kz3HB0
Non-physician health workers lead new approach to lowering risk of world’s number 1 cause of death, #cardiovasculardisease: HOPE 4, cluster-randomised controlled trial
Presenting now at #ESCCongress & free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0ky96x0
Presenting now at #ESCCongress & free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0ky96x0
Video abstract: Watch lead author Dr Jon-David Schwalm discuss HOPE 4, a community-based comprehensive intervention to reduce cardiovascular risk in hypertension
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kxb5F0
Free to read with reg until Sept 10 #LancetCardiology #ESCCongress hubs.ly/H0kxb5F0
Parallel community solutions for #cardiovascular risk reduction: Comment by Tazeen H Jafar, Zainab Samad & Gerald S Bloomfield on #ESCCongress presented HOPE 4 study
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kybJV0
Free to read with reg until Sept 10 #LancetCardiology hubs.ly/H0kybJV0
